Painreform Ltd Asset Resilience Ratio
Painreform Ltd asset resilience ratio. Painreform Ltd (PRFX) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PRFX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Painreform Ltd (2021–2023)
Asset resilience ratio of Painreform Ltd from 2021 to 2023. This chart shows how Painreform Ltd's Asset Resilience Ratio has changed over time. See Painreform Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Painreform Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PRFX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Painreform Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Painreform Ltd Industry Peers by Asset Resilience Ratio
Compare Painreform Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Painreform Ltd Asset Resilience Ratio by Year (2021–2023)
Painreform Ltd asset resilience ratio by year from 2021 to 2023. The table below shows the annual Asset Resilience Ratio data for Painreform Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $9.93 Million | -- |
| 2022-12-31 | 49.36% | $6.08 Million | $12.33 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $19.07 Million | -- |
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more